AVID BIOSERVICES INC (CDMO) Stock Price, Forecast & Analysis
USA - NASDAQ:CDMO - US05368M1062 - Common Stock
CDMO Key Statistics, Chart & Performance
The current stock price of CDMO is 12.49 USD. In the past month the price increased by 1.3%. In the past year, price increased by 85.86%.
CDMO Latest News, Press Relases and Analysis
CDMO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.21 | 404.22B | ||
| AMGN | AMGEN INC | 15.58 | 183.45B | ||
| GILD | GILEAD SCIENCES INC | 15.05 | 152.99B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.68 | 109.85B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.31 | 73.02B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 892.86 | 59.69B | ||
| INSM | INSMED INC | N/A | 41.38B | ||
| NTRA | NATERA INC | N/A | 28.72B | ||
| BIIB | BIOGEN INC | 9.68 | 23.76B | ||
| INCY | INCYTE CORP | 16.73 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.48 | 20.87B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.2 | 14.59B |
Related stock screener links
About CDMO
Company Profile
Avid Bioservices, Inc. engages in clinical and commercial manufacturing of biologics. The company is headquartered in Tustin, California and currently employs 371 full-time employees. The firm provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the Company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of its services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Commercial biologics produced by it are distributed to over 90 countries.
Company Info
AVID BIOSERVICES INC
14191 Myford Road
Tustin CALIFORNIA 92780 US
CEO: Nicholas S. Green
Employees: 371
Phone: 17145086100
AVID BIOSERVICES INC / CDMO FAQ
What does AVID BIOSERVICES INC do?
Avid Bioservices, Inc. engages in clinical and commercial manufacturing of biologics. The company is headquartered in Tustin, California and currently employs 371 full-time employees. The firm provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the Company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of its services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Commercial biologics produced by it are distributed to over 90 countries.
Can you provide the latest stock price for AVID BIOSERVICES INC?
The current stock price of CDMO is 12.49 USD. The price increased by 0.08% in the last trading session.
What is the dividend status of AVID BIOSERVICES INC?
CDMO does not pay a dividend.
What is the ChartMill technical and fundamental rating of CDMO stock?
CDMO has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for CDMO stock?
AVID BIOSERVICES INC (CDMO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.39).
Should I buy CDMO stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CDMO.
What is the expected growth for CDMO stock?
The Revenue of AVID BIOSERVICES INC (CDMO) is expected to grow by 17.28% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
CDMO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CDMO. When comparing the yearly performance of all stocks, CDMO is one of the better performing stocks in the market, outperforming 91.92% of all stocks.
CDMO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CDMO. Both the profitability and financial health of CDMO have multiple concerns.
CDMO Financial Highlights
Over the last trailing twelve months CDMO reported a non-GAAP Earnings per Share(EPS) of -2.39. The EPS decreased by -1305.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -47% | ||
| ROE | -339.34% | ||
| Debt/Equity | 3.58 |
CDMO Forecast & Estimates
11 analysts have analysed CDMO and the average price target is 12.75 USD. This implies a price increase of 2.08% is expected in the next year compared to the current price of 12.49.
For the next year, analysts expect an EPS growth of 86.15% and a revenue growth 17.28% for CDMO